rts logo

Which Institutions Own Shares In Pyxis Oncology Inc (PYXS)?

Pyxis Oncology Inc (NASDAQ: PYXS) is 209.44% higher on its value in year-to-date trading and has touched a low of $1.35 and a high of $6.85 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The PYXS stock was last observed hovering at around $5.38 in the last trading session, with the day’s gains setting it 0.19%.

Currently trading at $5.57, the stock is 9.38% and 16.99% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.13 million and changing 3.53% at the moment leaves the stock 102.40% off its SMA200. PYXS registered 38.90% gain for a year compared to 6-month gain of 171.71%. The firm has a 200-day simple moving average (SMA200) of -$2.68.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The stock witnessed a -13.91% loss in the last 1 month and extending the period to 3 months gives it a 170.39%, and is 45.43% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 14.15% over the week and 13.71% over the month.

Pyxis Oncology Inc (PYXS) has around 50 employees, a market worth around $323.78M and $0.00M in sales. Distance from 52-week low is 312.59% and -18.69% from its 52-week high. The company has generated returns on investments over the last 12 months (-50.61%).

Pyxis Oncology Inc quarterly earnings per share for the current quarter are estimated at -$0.24 with sales reaching $4.12M over the same period.The EPS is expected to grow by 42.03% this year

64 institutions hold shares in Pyxis Oncology Inc (PYXS), with institutional investors hold 38.24% of the company’s shares. The shares outstanding are 44.75M, and float is at 38.25M with Short Float at 4.27%. Institutions hold 29.84% of the Float.

The top institutional shareholder in the company is Laurion Capital Management, LP with over 3.17 million shares valued at $8.12 million. The investor’s holdings represent 8.02% of the PYXS Shares outstanding. As of Jun 29, 2023, the second largest holder is Tang Capital Management, LLC with 1.79 million shares valued at $4.58 million to account for 4.52% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 1.1 million shares representing 2.77% and valued at over $2.81 million, while Tekla Capital Management LLCC. holds 1.79% of the shares totaling 0.71 million with a market value of $1.81 million.

Pyxis Oncology Inc (PYXS) Insider Activity

The most recent transaction is an insider purchase by Connealy Pamela Ann, the company’s CFO and COO. SEC filings show that Connealy Pamela Ann bought 8,000 shares of the company’s common stock on Sep 28 ’23 at a price of $1.87 per share for a total of $14960.0. Following the purchase, the insider now owns 0.82 million shares.

Pyxis Oncology Inc disclosed in a document filed with the SEC on Sep 27 ’23 that Connealy Pamela Ann (CFO and COO) bought a total of 6,426 shares of the company’s common stock. The trade occurred on Sep 27 ’23 and was made at $1.85 per share for $11868.0. Following the transaction, the insider now directly holds 0.81 million shares of the PYXS stock.

Still, SEC filings show that on Sep 27 ’23, Wadhane Jitendra (Chief Accounting Officer) acquired 2,500 shares at an average price of $1.87 for $4675.0. The insider now directly holds 226,937 shares of Pyxis Oncology Inc (PYXS).

Related Posts